Non-culprit Vessels for ST-Segment Elevation Myocardial Infarction (CPVsSPCI)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02154919|
Recruitment Status : Completed
First Posted : June 3, 2014
Last Update Posted : June 3, 2014
|Condition or disease||Intervention/treatment|
|Conservative Pharmacotherapy Staged Percutaneous Coronary Intervention Non-culprit Vessels ST-Segment Elevation Myocardial Infarction||Procedure: Percutaneous coronary intervention|
|Study Type :||Observational|
|Actual Enrollment :||306 participants|
|Observational Model:||Case Control|
|Official Title:||Conservative Pharmacotherapy Versus Staged Percutaneous Coronary Intervention on Non-culprit Vessels for ST-Segment Elevation Myocardial Infarction Patients With Multivessel Disease|
|Study Start Date :||April 2011|
|Primary Completion Date :||December 2013|
complete revascularization group
this group underwent second PCI procedure on the non-culprit vessels and reveived 100-120 IU/kg unfractionated heparin during PPCI, followed by 3 days administration of low molecular weight heparin or Fondaparinux sodium after procedure. Patients in the CP group and CR group after second PCI procedure were given conservative medicine such as Statins which were not contraindicated to the patients.
|Procedure: Percutaneous coronary intervention|
conservative pharmacotherapy group
patients in conservative group undergoing pharmacotherapy after PPCI. The drugs were the same between two groups.
- Major Adverse Cardiovascular Events [ Time Frame: 360days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02154919
|Beijing Shijitan Hospital|
|Beijing, Beijing, China, 100038|